AbbVie Inc. stock: AbbVie announces ESMO data, slightly lower pre-market
Published on 10/20/2026 at 08:26 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSESMO program and October dates
- AbbVie announced on October 18, 2026, that it will present new and updated oncology data at ESMO.
- AbbVie’s third-quarter results are scheduled for October 30, 2026.
- AbbVie stock trades pre-market at EUR 252.40 at 8:23 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.16 percent below the Xetra close of October 19, 2026.
On October 18, 2026, AbbVie announced in a PR Newswire release that it would present new and updated oncology data at the European Society for Medical Oncology Congress. AbbVie stock trades pre-market at EUR 252.40 at 8:23 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.16 percent below the Xetra close of October 19, 2026 (EUR 252.80).
AbbVie outlines its ESMO program
The company said the October 23–27 congress in Madrid would feature data across seven assets and multiple tumor types, including Temab-A, ABBV-706, ABBV-969 and ABBV-1480. The release highlighted updated clinical, survival and biomarker data from investigational solid-tumor programs. MarketScreener reproduced the corrected release issued by AbbVie over PR Newswire.
Ahead of the Xetra open
The price is EUR 0.40 below the October 19 Xetra close. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of AbbVie stock.
Business and the day ahead
AbbVie develops innovative medicines through pharmaceutical research and development. The company’s calendar lists its third-quarter earnings release for October 30, 2026. AbbVie describes its work as developing medicines and solutions for serious health issues across areas including immunology, neuroscience and oncology.
Market context: Market report S&P 500.
